NLE Emergency & Critical Care Nursing — Shock, Sepsis & Multi-Organ DysfunctionSummary

Shock is defined as a pathophysiological state where oxygen delivery (DO₂) fails to meet cellular metabolic demand, forcing cells to shift from aerobic to anaerobic metabolism. This metabolic switch produces lactic acid accumulation (lactate >2 mmol/L), cellular dysfunction, and if uncorrected, organ failure and death. The critical distinction is that shock is not synonymous with hypotension—blood pressure may remain normal in early compensatory shock while perfusion is already failing at the cellular level. This is why a 'normal' blood pressure in a patient with clinical signs of poor perfusion (cool skin, delayed capillary refill, reduced urine output) is falsely reassuring. The nurse must recognize compensatory mechanisms as evidence of shock, not stability.

Hypovolemic shock results from loss of circulating volume from hemorrhage, severe dehydration, burn injuries, or third-spacing of fluid. Decreased intravascular volume reduces cardiac preload (right ventricular filling), which decreases stroke volume and cardiac output according to the Frank-Starling mechanism. The compensatory response produces tachycardia (HR >90), vasoconstriction (cool, clammy skin; delayed capillary refill >2 seconds), increased respiratory rate (RR >20), and oliguria (urine output <0.5 mL/kg/hr). Physical examination findings include flat neck veins, low central venous pressure (CVP <2 cmH₂O), and narrowed pulse pressure. Treatment focuses on rapid volume restoration using two large-bore peripheral IV lines or central access; initial crystalloid boluses of 500–1000 mL normal saline or lactated Ringer's infused rapidly, followed by blood products (packed RBCs, fresh frozen plasma) for hemorrhagic shock once crystalloid threshold is reached (~2 L). Hemorrhage control through direct pressure, tourniquet application, or surgical intervention addresses the source of continued loss.

Cardiogenic shock occurs when the cardiac pump fails despite adequate circulating volume, most commonly after acute myocardial infarction (MI) affecting >40% of left ventricular mass, but also in acute heart failure, severe arrhythmias, myocarditis, or valve rupture. The failing left ventricle cannot eject blood effectively, so preload and filling pressures rise while cardiac output falls. Clinical findings reflect this high-afterload, low-output state: hypotension, tachycardia, pale cool skin, crackles on lung auscultation (pulmonary edema from elevated left atrial pressure), jugular venous distension (JVD), elevated CVP (>8 cmH₂O), and elevated pulmonary artery wedge pressure (PAWP >18 mmHg). The critical nursing distinction is that aggressive fluid loading—appropriate in hypovolemia—worsens cardiogenic shock by further elevating filling pressures and worsening pulmonary congestion ('drowning the patient'). Management centers on supporting contractility with inotropes (dobutamine IV, which increases cardiac contractility and provides mild vasodilation), reducing cardiac workload with careful diuretics and vasodilators (nitroprusside, nitroglycerin), and addressing the underlying cause (urgent coronary revascularization in MI).

Distributive shock results from profound loss of vascular tone, causing massive vasodilation and pooling of blood in a dilated vasculature. Despite normal or high circulating volume, the expanded vascular space cannot be filled, so central venous pressure drops and tissue perfusion fails. Distributive shock has three critical subtypes: (1) Septic shock, caused by endotoxins and exotoxins from overwhelming infection that trigger release of inflammatory mediators (TNF-α, IL-1, IL-6) leading to vasodilation, capillary permeability (third-spacing), and myocardial depression; it is the most common shock type in ICU settings and has the highest mortality (30–50%). Early recognition and the sepsis bundle within the first hour are critical. (2) Neurogenic shock, occurring after high spinal cord injury (typically above T6) with loss of sympathetic outflow, causing unopposed parasympathetic effects and a unique clinical triad: hypotension, bradycardia (not tachycardia—this is the only shock type with bradycardia), and warm, dry skin. Management includes careful fluid resuscitation and vasopressors if needed, plus high-dose methylprednisolone if given within 8 hours of injury per older protocols (though recent evidence is mixed). (3) Anaphylactic shock, an IgE-mediated hypersensitivity reaction causing massive histamine release from mast cells and basophils, triggering sudden vasodilation, capillary leak, bronchospasm, and laryngeal edema. The priority drug is epinephrine 0.3–0.5 mg IM (1:1000 concentration) given intramuscularly (not IV initially) because IM penetrates deeply into muscle where it diffuses slowly, providing sustained effect; repeat every 5–15 minutes if symptoms persist. IV access is established for antihistamines (diphenhydramine) and corticosteroids (methylprednisolone) as adjuncts.

Obstructive shock occurs when a mechanical obstruction blocks blood flow through the heart or great vessels despite adequate pump function and adequate volume. The obstruction prevents flow forward, causing blood to back up behind the obstruction and systemic perfusion to fail. Key causes include tension pneumothorax (air in pleural space compressing the lung and shifting mediastinal structures, impeding venous return and cardiac filling), cardiac tamponade (fluid in the pericardial sac compressing the right atrium and ventricle, reducing diastolic filling), and massive pulmonary embolism (large thrombi or thrombi lodged in the pulmonary artery blocking right ventricular output). Clinical presentation includes hypotension, tachycardia, distended neck veins (elevated CVP from backup of blood), muffled heart sounds or Kussmaul's sign (paradoxical rise in CVP with inspiration in tamponade), and in tension pneumothorax, severe respiratory distress, tracheal deviation, and absent breath sounds unilaterally. The critical teaching point is that fluids and vasoactive drugs alone cannot relieve mechanical obstruction; the obstruction must be mechanically removed. Treatment includes needle decompression through the 2nd intercostal space midclavicular line (or 4th–5th space midaxillary) and chest tube placement for tension pneumothorax, emergency pericardiocentesis (pericardial tap) or surgical drainage for tamponade, and thrombolysis or embolectomy for massive PE.

All shock, regardless of cause, progresses through four predictable stages, and the window for successful intervention narrows at each step. Stage 1 (Initial stage): Tissue perfusion drops and cells shift to anaerobic metabolism, producing lactate. Clinical signs are absent—this is purely biochemical. Stage 2 (Compensatory stage): The body activates protective reflexes to maintain perfusion and blood pressure. Sympathetic nervous system activation causes tachycardia (HR >90), vasoconstriction (cool, pale, clammy skin; delayed capillary refill >2 seconds), increased respiratory rate (RR >20), and increased contractility. Renin-angiotensin-aldosterone system activation causes fluid retention and further vasoconstriction. Crucially, blood pressure is often maintained at this stage—this is the false reassurance that delays treatment. The earliest reliable clinical warnings are a rising respiratory rate (tachypnea often precedes tachycardia) and narrowing pulse pressure (the difference between systolic and diastolic BP narrows as diastolic pressure rises from vasoconstriction). Urine output falls (<0.5 mL/kg/hr). Anxiety and restlessness may appear as cerebral perfusion declines slightly. Stage 3 (Progressive stage): Compensatory mechanisms fail. Blood pressure falls despite continued sympathetic stimulation. Tissues become frankly ischemic; acidosis worsens from continued lactate production; organ perfusion declines. Mental status deteriorates (confusion, lethargy) from cerebral hypoperfusion. Organs begin to fail—urine output may cease entirely, liver transaminases rise, coagulation deteriorates. This stage is still potentially reversible with aggressive intervention, but the margin is narrow and outcomes are worse than if treated in Stage 2. Stage 4 (Refractory or irreversible stage): Cellular damage is so severe that the patient does not respond to any therapy—maximal fluids, vasopressors, and inotropes fail to restore perfusion. Organ failure becomes irreversible. Death is inevitable.

Sepsis exists on a continuum of the body's inflammatory response to infection. SIRS (systemic inflammatory response syndrome) is a generalized inflammatory state defined by meeting two or more of four criteria: core temperature >38°C or <36°C, heart rate >90 bpm, respiratory rate >20/min, and white cell count >12,000/μL or <4,000/μL. SIRS can be triggered by infection or by non-infectious insults (trauma, pancreatitis, post-operative state, burns), so SIRS alone does not confirm infection. Sepsis is defined as life-threatening organ dysfunction (failure of ≥1 organ) caused by a dysregulated host response to infection. The qSOFA (quick Sequential Organ Failure Assessment) tool screens for sepsis risk at the bedside: respiratory rate ≥22/min (indicating hypoxemia or metabolic acidosis), altered mentation (confusion, disorientation from hypoperfusion), and systolic blood pressure ≤100 mmHg. Two or more qSOFA criteria suggest high risk of sepsis and poor prognosis; these patients require immediate sepsis bundle initiation. Septic shock is sepsis with hypotension (SBP ≤100) requiring vasopressors to maintain MAP ≥65 mmHg, plus evidence of tissue hypoperfusion and metabolic derangement (elevated lactate >2 mmol/L) despite adequate fluid resuscitation. Septic shock carries mortality of 30–50% even with treatment, but early recognition and the sepsis bundle improve outcomes significantly.

Time is tissue in sepsis—each hour of delay increases mortality by approximately 7%. The sepsis bundle represents evidence-based care elements ideally initiated within the first hour of recognition: (1) Measure serum lactate and remeasure if elevated; lactate >2 mmol/L indicates tissue hypoperfusion and is a key trigger for aggressive resuscitation. (2) Obtain blood cultures from two separate sites before starting antibiotics—cultures obtained after antibiotics are started have dramatically lower yield and diagnostic value. However, culture collection must not delay antibiotics. (3) Administer broad-spectrum IV antibiotics (covering gram-positive, gram-negative, and anaerobic organisms) within 1 hour; delay is associated with increased mortality. For example, a patient with suspected intra-abdominal sepsis might receive ceftriaxone or a beta-lactam/beta-lactamase inhibitor (e.g., ampicillin-sulbactam) plus gentamicin or ciprofloxacin plus clindamycin, depending on local susceptibility patterns and hospital protocol. Antibiotics should be adjusted based on culture results and sensitivities within 48–72 hours. (4) Begin rapid crystalloid fluid resuscitation: 30 mL/kg of normal saline or lactated Ringer's for hypotension (SBP <100) or lactate ≥4 mmol/L, given as rapidly as tolerated (often 1–2 L over 15–30 minutes initially). Reassess response and continue titration. (5) Start vasopressors if hypotension persists during or after fluid resuscitation; norepinephrine is the first-line agent (target MAP ≥65 mmHg). The nursing sequence is critical: cultures obtained before antibiotics begin, but antibiotics must not be delayed waiting for every diagnostic test.

Norepinephrine (Levophed) is the first-line vasopressor in septic shock because of its balanced alpha-adrenergic (vasoconstriction) and beta-adrenergic (mild increase in contractility) effects. It is administered as a continuous IV infusion through central venous access (peripherally acceptable briefly), starting at 0.01–0.05 mcg/kg/min IV and titrated to achieve MAP ≥65 mmHg, often requiring doses of 0.1–0.5 mcg/kg/min or higher. Unlike pure alpha-agonists (phenylephrine), which cause vasoconstriction at the expense of cardiac output, norepinephrine restores both systemic vascular resistance and cardiac contractility. It improves coronary perfusion and splanchnic perfusion better than other agents. If norepinephrine fails to achieve target MAP, vasopressin (0.04 units/min fixed dose) or epinephrine can be added. Dobutamine, an inotrope that increases contractility and causes vasodilation, may be added if the patient has low cardiac output despite adequate MAP after fluid resuscitation and norepinephrine. However, dobutamine alone causes hypotension through vasodilation and is not used as monotherapy in septic shock.

MODS is defined as progressive, potentially reversible dysfunction of two or more organ systems arising from severe shock or sepsis that triggers uncontrolled systemic inflammation, microvascular injury, and organ ischemia. The typical sequence is: lungs first (acute respiratory distress syndrome [ARDS] with increased alveolar-capillary permeability, pulmonary edema, and refractory hypoxemia), then kidneys (acute kidney injury with rising creatinine and oliguria, progressing to anuria), liver (elevated transaminases, coagulopathy, hepatic encephalopathy), coagulation system (DIC with low platelets, fibrinogen, and prolonged PT/aPTT), gastrointestinal tract (ileus, translocation of bacteria across damaged mucosa, hepatic dysfunction from portal endotoxemia), and finally the heart (myocardial depression, cardiogenic shock). Mortality rises steeply with each additional failing organ: roughly 40% with one organ failing, 60% with two organs, 80% with three organs, and >90% with four or more organs. There is no specific cure for MODS—management is supportive care of each failing system (mechanical ventilation for ARDS, renal replacement therapy for AKI, vasopressors and inotropes for cardiovascular support, nutritional support), aggressive eradication of the underlying source (source control in sepsis), and prevention of secondary insults (avoiding aspiration, maintaining sterility of invasive lines, de-escalating antibiotics when appropriate).

DIC is a paradoxical coagulopathy in which widespread activation of the clotting cascade consumes platelets and clotting factors faster than they can be replaced, producing simultaneous microvascular thrombosis (plugging tiny vessels, worsening organ ischemia) and diffuse bleeding (because factors are consumed, bleeding cannot be controlled). DIC is always secondary to an underlying condition—severe sepsis (most common), major trauma, obstetric emergencies (amniotic fluid embolism, placental abruption, retained dead fetus), or hematologic malignancies. The patient may bleed from IV sites, mucous membranes, surgical wounds, and GI tract while microthrombi impair organ perfusion and worsen MODS. Laboratory findings are diagnostic: prolonged PT and aPTT (consumed factors), thrombocytopenia (low platelets, usually <100,000), low fibrinogen (<100 mg/dL is diagnostic; normal is 200–400), and elevated D-dimer or fibrin degradation products (indicating active fibrinolysis). The peripheral smear may show schistocytes (fragmented RBCs from passage through fibrin strands in microvasculature). The cornerstone of treatment is correcting the underlying cause—controlling infection in sepsis, arresting hemorrhage in trauma, delivering the baby in obstetric DIC. Supportive care replaces consumed components: fresh frozen plasma (10–15 mL/kg) for factor replacement, cryoprecipitate (10 units) if fibrinogen <100, and platelet transfusion for active bleeding with platelets <50,000. Anticoagulation with unfractionated heparin is reserved for thrombotic-predominant DIC (more common in chronic DIC with cancer) and is avoided in bleeding-predominant DIC until the underlying cause is controlled.

Hemodynamic monitoring guides shock resuscitation by assessing cardiac preload, contractility, afterload, and tissue perfusion. Basic monitoring includes blood pressure (manual or continuous), heart rate, central venous pressure (CVP via central line), and urine output. Advanced monitoring (available in intensive settings) includes pulmonary artery catheters (Swan-Ganz), which measure pulmonary artery occlusion pressure (PAWP, reflecting left ventricular preload), cardiac output by thermodilution, and systemic vascular resistance (SVR). Non-invasive alternatives include echocardiography and lactate measurement. Perfusion targets guiding therapy are: (1) Mean arterial pressure (MAP) ≥65 mmHg—this is the threshold to maintain organ perfusion; below 65 mmHg, critical organs (brain, kidney, heart) become ischemic. (2) Urine output ≥0.5 mL/kg/hr in adults (≥1 mL/kg/hr in children)—oliguria indicates inadequate renal perfusion and is a sensitive marker of underperfusion. Anuria (<100 mL/day) indicates severe shock or acute kidney injury. (3) Lactate <2 mmol/L and clearance of elevated lactate by >10% in 6 hours—lactate is a marker of anaerobic metabolism and tissue hypoperfusion. Persistent or rising lactate despite resuscitation indicates inadequate perfusion or progressive organ failure. (4) Skin perfusion assessment: warm extremities, normal capillary refill (<2 seconds), and absence of mottling indicate adequate perfusion; cool extremities, delayed capillary refill, and mottled skin indicate vasoconstriction and possible shock. (5) Mental status: alert and oriented indicates adequate cerebral perfusion; confusion or lethargy indicates hypoperfusion.

Lactate is produced when cells shift to anaerobic metabolism due to inadequate oxygen delivery. In shock, lactate is elevated (>2 mmol/L) and rises with increasing severity. Persistently elevated lactate despite aggressive resuscitation indicates ongoing tissue hypoperfusion or end-organ damage and predicts poor outcomes. Lactate clearance (decline by >10% in 6 hours) is a marker of improving perfusion. In septic shock, lactate-guided resuscitation (targeting lactate clearance, not just MAP and urine output) improves outcomes. Serial lactate measurements (initial, 6 hours, 24 hours) track the trajectory and adequacy of resuscitation.